...
Becky Upton Mark Livingstone (Unlicensed)
The innovation team: projectenquiries@pistoiaalliance.org
Problem Statement
Commercially purchased biological reagents come with a variety of restrictions, including Nagoya Protocol restrictions, usage limits, shipping restrictions, etc.
Scientists have difficulty finding & understanding these restrictions, resulting in slower lab work + higher risk of non-compliance.
We imagine this problem is similar across Pharmaceutical companies – small “cottage industries” in each company must analyze bio-licensing restrictions on a case-by-case basis.
...